Navigating 5 Analyst Ratings For Harrow
Portfolio Pulse from Benzinga Insights
Five analysts have recently rated Harrow (NASDAQ:HROW), with all ratings being bullish. The average 12-month price target has increased to $40.00, with a high of $50.00 and a low of $25.00. Analysts have raised their price targets, reflecting positive sentiment. Harrow, an eyecare pharmaceutical company, has shown strong revenue growth but faces challenges in debt management and returns on equity and assets.
August 29, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Harrow has received bullish ratings from 5 analysts, with an increased average price target of $40.00. Analysts have raised their price targets, indicating positive sentiment. Despite strong revenue growth, Harrow faces challenges in debt management and returns on equity and assets.
The unanimous bullish ratings and increased price targets from analysts suggest a positive short-term outlook for Harrow's stock. The company's strong revenue growth supports this sentiment. However, challenges in debt management and returns on equity and assets may temper long-term expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100